Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,821 to 2,840 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 64 of 1,288 48 of 1,303 | 1.3 points -0.3 to 2.9 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 14 of 1,288 3 of 1,303 | 0.9 points 0.2 to 1.6 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 57 of 1,288 47 of 1,303 | 0.8 points -0.7 to 2.4 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Rehospitalization | 66 of 1,288 59 of 1,302 | 0.6 points -1.1 to 2.3 | 2,590 | NCT02173379 Absorb IV Randomized Controlled Trial |
| An Informational Packet Regarding Shingles and the HZV vs Standard Medical Care From Their Primary Care Physician: Number of Participants Who Received the Herpes Zoster Vaccine | 500 of 500 2,089 of 2,089 | 0.0 points -0.8 to 0.2 | 2,589 | NCT01519570 Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates |
| Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography | 18 of 1,288 21 of 1,301 | -0.2 points -1.2 to 0.8 | 2,589 | NCT02173379 Absorb IV Randomized Controlled Trial |
| AC Then T vs AC Then XT: serious adverse events | 264 of 1,305 200 of 1,283 | 4.6 points 1.7 to 7.6 | 2,588 | NCT00089479 A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer |
| aTIV (Pooled) vs Licensed TIV: Number of High Risk Subjects With Exacerbation of Preexisting Chronic Disease, Across Vaccine Groups | 55 of 1,307 48 of 1,281 | 0.5 points -1.1 to 2.0 | 2,588 | NCT01162122 Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects |
| This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 30-day Point Prevalence Abstinence (ITT) | 314 of 1,304 239 of 1,284 | 5.5 points 2.3 to 8.6 | 2,588 | NCT04251273 Text Message Quit Vaping Intervention for Young Adults |
| This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 7-day Point Prevalence Abstinence (ITT) | 440 of 1,304 385 of 1,284 | 3.8 points 0.2 to 7.3 | 2,588 | NCT04251273 Text Message Quit Vaping Intervention for Young Adults |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 71 of 1,286 53 of 1,300 | 1.4 points -0.2 to 3.1 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 66 of 1,286 50 of 1,300 | 1.3 points -0.3 to 2.9 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 28 of 1,286 15 of 1,300 | 1.0 points 0.0 to 2.1 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants withTarget Lesion Revascularization (TLR) | 16 of 1,286 4 of 1,300 | 0.9 points 0.3 to 1.7 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 15 of 1,286 4 of 1,300 | 0.9 points 0.2 to 1.6 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 81 of 1,286 65 of 1,300 | 1.3 points -0.5 to 3.1 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 67 of 1,286 53 of 1,300 | 1.1 points -0.5 to 2.8 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 5 of 1,286 5 of 1,300 | 0.0 points -0.6 to 0.6 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 77 of 1,286 59 of 1,300 | 1.4 points -0.3 to 3.2 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE) | 74 of 1,286 55 of 1,300 | 1.5 points -0.2 to 3.2 | 2,586 | NCT02173379 Absorb IV Randomized Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=142"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=142
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02173379-d80d7574",
"title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)",
"summary": "64 of 1288 against 48 of 1303; risk difference 1.3 points, 95% interval -0.3 to 2.9; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-d80d7574",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2591,
"risk_difference": {
"value": 0.012851374992253896,
"lower": -0.0029005434797239084,
"upper": 0.028847892149882422
},
"group_1": "64 of 1,288",
"group_2": "48 of 1,303",
"difference": "1.3 points",
"interval": "-0.3 to 2.9",
"trial_title": "Absorb IV Randomized Controlled Trial"
},
{
"id": "NCT02173379-ed34aa5b",
"title": "Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)",
"summary": "14 of 1288 against 3 of 1303; risk difference 0.9 points, 95% interval 0.2 to 1.6; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-ed34aa5b",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2591,
"risk_difference": {
"value": 0.008567186092295372,
"lower": 0.0023240775394892726,
"upper": 0.016016552121647265
},
"group_1": "14 of 1,288",
"group_2": "3 of 1,303",
"difference": "0.9 points",
"interval": "0.2 to 1.6",
"trial_title": "Absorb IV Randomized Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=143",
"request_id": "vEibArEgapdfItdj"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant